LUMIZYME (alglucosidase alfa)
for the rare but debilitating enzyme
deficiency Pompe disease, has been
approved for expanded use to now
include patients less than eight years
of age by the US Food and Drug
Administration (FDA).
Lumizyme is marketed in Australia
as Myozyme and has been
approved by the Therapeutic Goods
Administration since 14 Mar 2008.
The FDA also approved Jardiance
(empagliflozin) tablets, marketed as
Ronjoli in Australia, as an addition
to diet and exercise to improve
glycemic control in adults with type
2 diabetes.The above article was sent to subscribers in Pharmacy Daily's issue from 05 Aug 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Aug 14
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.